Hycamtin
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Topotecan
- Made by
- Sandoz Pharmaceuticals d.d.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (HYCAMTIN). It describes the substance, not this exact product.
Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.
Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these single-strand breaks.
Food Effect Following a high-fat meal, the AUC was similar in the fed and fasted states, while T max was delayed from 1.5 to 3 hours for topotecan lactone and from 3 to 4 hours for total topotecan.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2023-09-18
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sandoz Pharmaceuticals d.d. |
|---|---|
| Active substance | Topotecan |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01CE01 · Cancer treatments and immune-system medicines |
| Authorised on | 1996-11-12 |
| Last updated by the regulator | 2026-01-20 |
| EMA product number | EMEA/H/C/000123 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.